FDA approves Roche’s kidney inflammation drug
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Expanding US operations to address the increased demand for API development and manufacturing
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Subscribe To Our Newsletter & Stay Updated